ReviewExpert opinion on pharmacotherapy2013
Pharmacotherapy of scleritis: current paradigms and future directions.
Review in Expert opinion on pharmacotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- Trigeminal sensory neuropathy developing as a late complication after the treatment of surgically induced necrotizing scleritis following pterygium surgery: a case report and literature review.BMC ophthalmology · 2026Review
- An Overview of Rheumatoid Arthritis-Associated Dry Eye Disease, Scleritis, and Peripheral Ulcerative Keratitis.Journal of clinical medicine · 2026Review
- Sequential ocular surgeries and multimodal immunosuppression for bilateral, medically refractory seronegative scleritis with severe peripheral corneal stromal thinning: a case report.BMC ophthalmology · 2026Article
- Article
- Update on Therapy for Non-Infectious Scleritis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- SEVERE CIRCULATORY DISTURBANCE IN OPTIC DISK, RETINA, AND CHOROID AFTER SUB-TENON TRIAMCINOLONE ACETONIDE INJECTION FOR POSTERIOR SCLERITIS.Retinal cases & brief reports · 2025Review
- Article
- Article
- A novel technique of full-thickness scleral debridement in fulminant necrotising infectious scleritis and its outcomes-a consecutive case series.International ophthalmology · 2022Article
- Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.Ophthalmology and therapy · 2021Review
- Scleritis and sclerokeratitis associated with IgA vasculitis: A case series.American journal of ophthalmology case reports · 2021Article
- Measurements of scleral thickness and corneal optic densitometry in patients with systemic lupus erythematosus.Medicine · 2020Article
- More Than Meets the Eye: A Rare Case of Posterior Scleritis Masquerading as Orbital Cellulitis.Cureus · 2020Article
- Effectiveness of pharmacological agents for the treatment of non-infectious scleritis: a systematic review protocol.Systematic reviews · 2020Article
- Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options.Neuronal signaling · 2018Review
- Flurbiprofen: A Nonselective Cyclooxygenase (COX) Inhibitor for Treatment of Noninfectious, Non-necrotizing Anterior Scleritis.Ocular immunology and inflammation · 2016Article
- Biologic therapy for refractory scleritis: a new treatment perspective.International ophthalmology · 2015Review
- Nodular anterior scleritis associated with Berger's disease.Arquivos brasileiros de oftalmologiaArticle
- Clinical spectrum and management of anterior scleritis: case reports.Therapeutic advances in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
introductionScleritis is an inflammatory condition affecting the eye wall that may be associated with a number of systemic inflammatory diseases. Because scleritis can be refractory to standard treatment, knowledge of the body of available and emerging therapies is paramount and is reviewed here. AREAS COVERED: This review focuses on both traditional and emerging therapies for noninfectious scleritis. The authors cover the mechanisms of action and potential adverse effects of each of the treatment modalities. In addition, a summary of the significant MEDLINE indexed literature under the subject heading 'scleritis', 'treatment', 'immunomodulator' will be provided on each therapy, including commentary on appropriate use and relative contraindications. Novel treatments and potential drug candidates that are currently being evaluated in clinical trials with therapeutic potential will also be reviewed. EXPERT OPINION: While oral nonsteroidal anti-inflammatory drugs and oral corticosteroids are widely used, effective, first-line agents for inflammatory scleritis, refractory cases require antimetabolites, T-cell inhibitors, or biologic response modifiers. In particular, there is emerging evidence for the use of targeted biologic response modifiers, and potentially, for local drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.